A class of drugs originally developed to manage blood sugar in type 2 diabetes is now reshaping how doctors think about cardiovascular death, and the implications stretch well beyond endocrinology. Sotagliflozin, marketed as Inpefa, demonstrated a 23 percent reduction in the rate of heart attacks, strokes, and deaths from cardiovascular causes compared to placebo in patients with chronic kidney disease, type 2 diabetes, and cardiovascular risk factors. That finding, published in February 2025 in The Lancet Diabetes & Endocrinology, makes it the first and only SGLT inhibitor to significantly reduce both heart attacks and strokes — a dual benefit no other drug in its class has achieved. For the millions of older adults managing kidney disease alongside cognitive decline, this cardiovascular protection could be quietly consequential. Vascular health and brain health are deeply intertwined, and anything that reduces stroke risk and cardiovascular mortality deserves close attention from those concerned about dementia. Sotagliflozin is not alone in this space.
Semaglutide, empagliflozin, and dapagliflozin have each demonstrated meaningful cardiovascular benefits in large-scale kidney disease trials. The FLOW trial for semaglutide showed a 29 percent reduction in cardiovascular death. The EMPA-KIDNEY trial for empagliflozin found a 28 percent reduction in kidney disease progression or cardiovascular death. These are not marginal gains. They represent a genuine shift in how chronic kidney disease is treated, with cardiovascular protection now considered a central — not secondary — benefit. This article walks through the evidence behind each drug, what distinguishes sotagliflozin from its competitors, the brain health implications of reduced cardiovascular events, and what patients and caregivers should know about this evolving standard of care.
Table of Contents
- How Are Kidney Drugs Reducing Cardiovascular Deaths in High-Risk Patients?
- What the Major Trials Actually Showed — and Where the Evidence Has Limits
- The Brain Health Connection That Nephrologists Are Not Talking About
- Comparing the Options — Which Drug Fits Which Patient?
- What Can Go Wrong — Warnings for Older Adults and Dementia Patients
- What the New Guidelines Mean for CKD Patients Already on Multiple Medications
- Where This Field Is Heading — Trials to Watch
- Conclusion
- Frequently Asked Questions
How Are Kidney Drugs Reducing Cardiovascular Deaths in High-Risk Patients?
The answer lies in a protein-blocking mechanism that does more than lower blood sugar. SGLT2 inhibitors work by preventing the kidneys from reabsorbing glucose, which gets excreted in urine instead. But the cardiovascular benefits appear to operate independently of glucose control — they reduce fluid overload, lower blood pressure, decrease arterial stiffness, and improve how the heart handles energy at a cellular level. this is why the 2026 ADA Standards of Care and 2024 KDIGO Guidelines now recommend SGLT2 inhibitors as foundational therapy for chronic kidney disease patients with or without diabetes. The cardiovascular and kidney protection these drugs provide is not a side effect of blood sugar management. It is a standalone clinical benefit. Sotagliflozin stands apart because it blocks both SGLT1 and SGLT2 proteins, while drugs like empagliflozin and dapagliflozin only block SGLT2. The SGLT1 receptor sits primarily in the gut, where it regulates glucose and sodium absorption after meals.
By hitting both targets, sotagliflozin appears to blunt post-meal glucose and sodium spikes more effectively, which may explain its unique ability to reduce heart attacks and strokes simultaneously. The SCORED trial — which enrolled 10,584 patients with chronic kidney disease, type 2 diabetes, and cardiovascular risk factors — was led by Dr. Deepak L. Bhatt, Director of Mount Sinai’s Fuster Heart Hospital, and it is the dataset behind those headline numbers. For context, compare that to dapagliflozin’s DAPA-CKD trial, which showed an 18 percent relative risk reduction in cardiovascular death and a 17 percent reduction in all-cause mortality. Those are strong results, but they did not show statistically significant reductions in heart attacks or strokes individually. The distinction matters. A drug that prevents heart failure hospitalizations is valuable. A drug that also prevents the stroke that could trigger vascular dementia is operating on a different level entirely.
What the Major Trials Actually Showed — and Where the Evidence Has Limits
The evidence base here is unusually robust by pharmaceutical standards, but it is not without caveats. The SCORED trial for sotagliflozin was cut short due to loss of funding during the pandemic, which means the 23 percent reduction in major adverse cardiovascular events was observed over a shorter follow-up period than originally planned. The results were statistically significant, but a longer trial might have revealed whether the benefit grows, plateaus, or diminishes over time. The companion SOLOIST-WHF trial, which focused on patients recently hospitalized for heart failure, showed a 33 percent reduction in the composite of heart failure hospitalization, urgent heart failure visits, and cardiovascular death — again impressive, but also truncated early. Semaglutide’s FLOW trial had a more complete run. It followed 3,533 participants for a median of 3.4 years and found a 24 percent reduction in its composite primary endpoint of kidney outcomes and cardiovascular or kidney death.
Cardiovascular death specifically dropped by 29 percent, major cardiovascular events fell by 18 percent, and all-cause mortality decreased by 20 percent. Published in the new England Journal of Medicine in 2024, it was the first dedicated kidney outcomes trial with a GLP-1 receptor agonist. In January 2025, the FDA expanded semaglutide’s indication to include adults with type 2 diabetes and chronic kidney disease, specifically for reducing the risk of worsening kidney disease and cardiovascular death. However, if a patient does not have type 2 diabetes, the semaglutide data does not directly apply. The FLOW trial enrolled only patients with type 2 diabetes and CKD. Dapagliflozin, by contrast, showed cardiovascular and kidney benefits regardless of whether the patient had diabetes — a critical distinction for the many older adults with kidney disease from causes other than diabetes. Clinicians making prescribing decisions need to weigh which drug fits the patient in front of them, not which drug produced the most dramatic headline number.
The Brain Health Connection That Nephrologists Are Not Talking About
Chronic kidney disease and dementia share a vascular substrate. The small blood vessels in the kidneys and the brain are structurally similar, and the same processes that damage one tend to damage the other — hypertension, diabetes, atherosclerosis, chronic inflammation. Epidemiological data has consistently shown that patients with CKD have higher rates of cognitive impairment and dementia than the general population. Anything that protects the cardiovascular system in these patients is, at least theoretically, also protecting the brain. Consider stroke specifically. Stroke is the second leading cause of dementia worldwide, and it is a primary driver of vascular cognitive impairment.
Sotagliflozin’s demonstrated ability to significantly reduce stroke incidence — not just heart failure or composite endpoints, but strokes — makes it uniquely relevant to brain health conversations. A 70-year-old with CKD, type 2 diabetes, and mild cognitive impairment is exactly the kind of patient for whom preventing a stroke could mean the difference between stable cognition and rapid decline into vascular dementia. No one has yet run a trial specifically testing whether SGLT inhibitors prevent dementia. That research gap matters, and it should temper any enthusiasm. But the mechanistic logic is sound, and the cardiovascular data is strong enough that some geriatric specialists are already factoring stroke reduction into their prescribing calculus for patients at high dementia risk. The empagliflozin EMPA-KIDNEY trial showed cardiovascular death rates of 3.8 percent in the treatment group versus 4.9 percent in the placebo group, with benefits persisting up to one year after patients stopped taking the drug. That kind of durable protection has obvious implications for long-term brain health, even if the direct evidence is not yet in hand.
Comparing the Options — Which Drug Fits Which Patient?
Choosing between sotagliflozin, semaglutide, empagliflozin, and dapagliflozin is not a matter of picking the one with the biggest percentage reduction. Each drug has a different trial population, a different mechanism, and a different side-effect profile. Sotagliflozin’s dual SGLT1/SGLT2 blockade gives it the broadest cardiovascular signal — reducing both heart attacks and strokes — but it also comes with higher rates of diarrhea due to the SGLT1 gut mechanism. For an elderly patient already prone to dehydration or falls, that gastrointestinal side effect is not trivial. Semaglutide is a GLP-1 receptor agonist, not an SGLT2 inhibitor, so it operates through an entirely different pathway.
Its 29 percent reduction in cardiovascular death in the FLOW trial is compelling, but it requires subcutaneous injection and carries risks of nausea, pancreatitis, and — in rare cases — thyroid tumors flagged in animal studies. Empagliflozin and dapagliflozin are oral medications with generally well-tolerated profiles, though they carry risks of urinary tract infections and, rarely, diabetic ketoacidosis. Dapagliflozin’s advantage is that its benefits in the DAPA-CKD trial were observed regardless of diabetes status, making it the go-to option for CKD patients whose kidney disease stems from non-diabetic causes. For caregivers managing a loved one with both kidney disease and cognitive decline, the practical question is often simpler: can this person reliably take the medication, and will the side effects create new problems? A drug that causes persistent diarrhea in a patient with balance issues and cognitive impairment can lead to dehydration, falls, and hospitalization — outcomes that negate the cardiovascular benefit. These tradeoffs should be discussed explicitly with the prescribing physician.
What Can Go Wrong — Warnings for Older Adults and Dementia Patients
SGLT2 inhibitors carry a well-documented risk of volume depletion. They work partly by causing the kidneys to excrete more fluid, which lowers blood pressure — generally a good thing, but dangerous in patients who are already on diuretics, have poor fluid intake, or cannot reliably communicate thirst. Older adults with dementia are disproportionately vulnerable on all three counts. Dehydration in this population can trigger acute kidney injury, delirium, and falls, each of which can accelerate cognitive decline. There is also the issue of diabetic ketoacidosis, which can occur even when blood sugar levels appear normal — so-called euglycemic DKA.
It is rare, but it is more likely in patients who are eating poorly, have been ill, or have recently had surgery. Caregivers and clinicians need to be aware that a patient on an SGLT2 inhibitor who becomes confused or nauseated may be in ketoacidosis even if their glucose readings look fine. This is particularly treacherous in dementia patients, where new confusion can easily be attributed to disease progression rather than a medical emergency. Finally, the FDA-approved indication for sotagliflozin — granted in May 2023 under the brand name Inpefa — is specifically for decreasing the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits. It is not approved for dementia prevention, cognitive protection, or as a general-purpose cardiovascular drug for all older adults. Prescribing it off-label for brain health reasons alone would be premature, and patients or caregivers who raise this possibility with their doctor should expect a nuanced conversation about risks, benefits, and the current limits of the evidence.
What the New Guidelines Mean for CKD Patients Already on Multiple Medications
The 2026 ADA Standards of Care and the 2024 KDIGO Guidelines now position SGLT2 inhibitors as foundational therapy for CKD — not an add-on, not a second-line option, but a cornerstone of treatment. For patients already taking ACE inhibitors, statins, blood thinners, and cholinesterase inhibitors for dementia, adding another medication raises legitimate polypharmacy concerns. Drug interactions with SGLT2 inhibitors are relatively few, but the cumulative burden of multiple medications — each with its own side effects, dosing schedule, and monitoring requirements — is a practical barrier that clinical guidelines do not always address.
A patient taking donepezil for Alzheimer’s, lisinopril for blood pressure, atorvastatin for cholesterol, and now dapagliflozin for kidney protection is on four medications with four different risk profiles. Caregivers managing this regimen need clear instructions about when to hold doses — for instance, stopping the SGLT2 inhibitor temporarily during acute illness to prevent dehydration and ketoacidosis. This kind of proactive medication management is where the real-world benefit of these drugs is either realized or lost.
Where This Field Is Heading — Trials to Watch
The next frontier is whether these cardiovascular benefits translate directly into measurable cognitive protection. Several observational studies are already underway examining whether patients on SGLT2 inhibitors show slower rates of cognitive decline than matched controls. If those signal positive results, randomized controlled trials specifically designed to test dementia prevention with these drugs could follow. The mechanistic rationale — reduced stroke, lower blood pressure, less vascular inflammation, improved kidney function — aligns with nearly every modifiable risk factor for vascular dementia and mixed dementia. There is also growing interest in whether sotagliflozin’s dual SGLT1/SGLT2 mechanism offers advantages beyond what SGLT2-only inhibitors provide.
The gut-level SGLT1 blockade reduces post-meal glucose and sodium surges, which contribute to endothelial damage over time. If that translates to better preservation of small-vessel integrity in the brain, sotagliflozin could eventually become the preferred agent for patients at high risk of both cardiovascular events and cognitive decline. But that is a hypothesis, not a conclusion. The data that exists today supports using these drugs for kidney and heart protection. The brain health argument remains promising but unproven.
Conclusion
The evidence is now strong enough that kidney drugs — particularly SGLT2 inhibitors and sotagliflozin’s dual SGLT1/SGLT2 approach — should be part of every serious conversation about cardiovascular risk in patients with chronic kidney disease. Sotagliflozin’s 23 percent reduction in major cardiovascular events, semaglutide’s 29 percent reduction in cardiovascular death, and dapagliflozin’s benefits regardless of diabetes status represent a class of medications that has exceeded its original purpose. For families navigating both kidney disease and dementia, the stroke reduction data is particularly relevant, even as we wait for direct evidence of cognitive protection. Talk to your loved one’s nephrologist or cardiologist about whether an SGLT2 inhibitor or sotagliflozin specifically is appropriate given their full medical picture.
Ask about hydration monitoring, ketoacidosis warning signs, and how the new medication fits with existing prescriptions. These drugs are not a cure for dementia, and they are not without risk. But they represent one of the few pharmacological interventions that protects the heart, the kidneys, and — quite possibly — the brain, all at once. In a field where meaningful progress is measured in single-digit percentage improvements, reductions of 20 to 33 percent are worth paying attention to.
Frequently Asked Questions
Are SGLT2 inhibitors approved for dementia prevention?
No. These drugs are approved for managing type 2 diabetes, chronic kidney disease, and heart failure. Any cognitive benefit is theoretical at this point, based on their demonstrated ability to reduce strokes and cardiovascular deaths. No regulatory agency has approved them for dementia prevention or cognitive protection.
Can someone without diabetes take these kidney drugs for cardiovascular protection?
It depends on the specific drug. Dapagliflozin showed cardiovascular and kidney benefits regardless of diabetes status in the DAPA-CKD trial. Semaglutide’s FLOW trial, however, only enrolled patients with type 2 diabetes, so its results do not directly apply to non-diabetic patients. Your doctor can determine which drug fits your situation.
What is the difference between sotagliflozin and other SGLT2 inhibitors like empagliflozin?
Sotagliflozin blocks both SGLT1 and SGLT2 proteins, while empagliflozin and dapagliflozin only block SGLT2. This dual mechanism appears to give sotagliflozin a broader cardiovascular benefit — it is the only drug in the class that has significantly reduced both heart attacks and strokes in clinical trials.
What side effects should dementia caregivers watch for?
The most concerning side effects for older adults with cognitive impairment are dehydration, diarrhea (especially with sotagliflozin), urinary tract infections, and euglycemic diabetic ketoacidosis — a rare condition where ketoacidosis occurs even with normal-looking blood sugar. New or worsening confusion in a patient on these drugs should be evaluated medically, not assumed to be dementia progression.
How long do the cardiovascular benefits last after stopping the medication?
The EMPA-KIDNEY trial found that empagliflozin’s benefits persisted up to one year after patients stopped treatment. This suggests the drugs may produce durable changes in cardiovascular and kidney health, though long-term data beyond one year post-cessation is limited.
